Ignite Creation Date:
2025-12-25 @ 12:04 AM
Ignite Modification Date:
2026-02-26 @ 12:36 AM
Study NCT ID:
NCT04108858
Status:
TERMINATED
Last Update Posted:
2025-10-01
First Post:
2019-09-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-05-20
Start Date Type:
ACTUAL
Primary Completion Date:
2022-04-29
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-04-29
Completion Date Type:
ACTUAL
First Submit Date:
2019-09-27
First Submit QC Date:
None
Study First Post Date:
2019-09-30
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-01-11
Results First Submit QC Date:
None
Results First Post Date:
2024-06-27
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-12
Last Update Post Date:
2025-10-01
Last Update Post Date Type:
ESTIMATED